The risk of recurrence is determined by tumor size, number of lymph node metastases, histological malignancy, Ki67 proliferation status, hormone receptor (HR) and human epidermal growth factor receptor (HER)2 expression level, vascular invasion, and mutations in cancer-related genes [5–7]. The gene discussed is ERBB2; the disease is neoplasm.